Delhi: A new class of diabetes drugs are indeed bringing a sense of relief to the Indian Diabetics. While on one hand these drugs are an advancement over the old class of drugs, the new molecule also costs less, leading to a fall in prices of these new varieties. This new class of drug belongs to the Gliptin family
The prices of medicine for the disease is reported to have gone down from Rs. 156 per pack in January to Rs. 79 in the month of September, marking a huge steep.
The reason for the said fall in prices of the diabetes medicines is introduction of a new class of molecule belonging to the gliptin family, which is helpful in the cure. About 1.85 million diabetics, who are on gliptin therapy to manage their type-2 diabetes will be benefited with this advent.
The therapy using this molecule which is launched as a breakthrough in diabetes treatment does not have any side effects according to the experts.This indeed is another advantage of the new drug.
“The country’s anti-diabetes market is one of the fastest-growing segments, with a growth rate exceeding 25% at Rs 7,638 crore,” says data of the All India Organisation of Chemists and Druggists Association.
More than 34 brands are prepared from the teneligliptin molecule, under the name of 30 companies including Glenmark, Mankind Pharma, Zydus, Eris Life Sciences and Intas.
Glenmark Pharmaceuticals chairman, Glenn Saldanha told HT, “While most of the gliptins were imported, teneligliptin is the only gliptin to be manufactured in India. With the launch of this, the daily cost of treatment for gliptin therapy has come down dramatically,” Mankind Pharmaceuticals is expecting the prices to fall more.
The average price for older drugs was Rs. 45 per day, while the new drugs, which are based on teneligliptin has reduced prices with its advent to Rs. 5 to Rs. 7 per day.
The drug was launched by Glenmark last year under brands including Ziten and Zita Plus costing Rs 19.90 per tablet. Most gliptins on the other hand were priced at around Rs 45.
“We are planning to manufacture this molecule (bulk drug) at our new plant, which is set to start in January. We may see further cost benefits that may allow prices to reduce further,” stated RC Juneja, the chief executive officer of Mankind Pharma.
The prices of medicine for the disease is reported to have gone down from Rs. 156 per pack in January to Rs. 79 in the month of September, marking a huge steep.
The reason for the said fall in prices of the diabetes medicines is introduction of a new class of molecule belonging to the gliptin family, which is helpful in the cure. About 1.85 million diabetics, who are on gliptin therapy to manage their type-2 diabetes will be benefited with this advent.
The therapy using this molecule which is launched as a breakthrough in diabetes treatment does not have any side effects according to the experts.This indeed is another advantage of the new drug.
“The country’s anti-diabetes market is one of the fastest-growing segments, with a growth rate exceeding 25% at Rs 7,638 crore,” says data of the All India Organisation of Chemists and Druggists Association.
More than 34 brands are prepared from the teneligliptin molecule, under the name of 30 companies including Glenmark, Mankind Pharma, Zydus, Eris Life Sciences and Intas.
Glenmark Pharmaceuticals chairman, Glenn Saldanha told HT, “While most of the gliptins were imported, teneligliptin is the only gliptin to be manufactured in India. With the launch of this, the daily cost of treatment for gliptin therapy has come down dramatically,” Mankind Pharmaceuticals is expecting the prices to fall more.
The average price for older drugs was Rs. 45 per day, while the new drugs, which are based on teneligliptin has reduced prices with its advent to Rs. 5 to Rs. 7 per day.
The drug was launched by Glenmark last year under brands including Ziten and Zita Plus costing Rs 19.90 per tablet. Most gliptins on the other hand were priced at around Rs 45.
“We are planning to manufacture this molecule (bulk drug) at our new plant, which is set to start in January. We may see further cost benefits that may allow prices to reduce further,” stated RC Juneja, the chief executive officer of Mankind Pharma.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd